Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

NCT04331093 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
40
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Di Wu